GlaxoSmithKline Start Second Phase Study of Antibody For Inflammatory Osteoarthritis
18 April 2016 - 8:21PM
Dow Jones News
LONDON--GlaxoSmithKline PLC (GSK.LN) Monday said it has started
a second phase study to evaluate the efficacy and safety of an
antibody in patients with inflammatory hand osteoarthritis.
The healthcare company said the main objective of the
randomized, placebo-controlled and parallel-group study is to
assess the efficacy potential of subcutaneous injections of the
antibody on pain. The secondary objectives is to assess the safety
and pharmacokinetics of the antibody, the company said.
Shares at 0950 GMT up 2.50 pence, or 0.2%, at 1,508.50 pence
valuing the company at 73.5 billion pounds ($104.66 billion).
Write to Olga Cotaga at olga.cotaga@wsj.com, Twitter
@OlgaCotaga
(END) Dow Jones Newswires
April 18, 2016 06:06 ET (10:06 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Apr 2024 to May 2024
GSK (NYSE:GSK)
Historical Stock Chart
From May 2023 to May 2024